Press release
Cell and Gene Therapy in Parkinson's Disease Market Growth, Applications, Innovations and Business Outlook by 2034
Cell and Gene Therapy in Parkinson's Disease Market
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor symptoms such as tremors, rigidity, and bradykinesia, along with non-motor symptoms including cognitive impairment and depression. Current therapies primarily manage symptoms but do not halt disease progression.
The advent of cell and gene therapies is redefining the treatment paradigm for Parkinson's disease. These advanced approaches target the underlying pathology by restoring dopamine production, repairing neuronal circuits, or delivering neuroprotective factors. With strong clinical trial pipelines and rising investment in advanced therapies, the cell and gene therapy in Parkinson's disease market is poised for significant expansion.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/72098
Market Overview
The global cell and gene therapy in Parkinson's disease market was valued at USD 1.9 billion in 2024 and is projected to reach USD 5.2 billion by 2034, expanding at a Compound Annual Growth Rate (CAGR) of 10.5% during the forecast period.
Key market highlights include:
• Increasing prevalence of Parkinson's disease worldwide, affecting over 10 million people.
• Rapid advancements in gene editing and cell transplantation technologies.
• Strong funding for clinical trials and collaborations between pharma, biotech, and academic institutions.
• Growing regulatory support for advanced therapy medicinal products (ATMPs).
Challenges include high treatment costs, long clinical development timelines, and the complexity of large-scale manufacturing for cell and gene therapies.
Leading players include Novartis AG, Bayer AG, BlueRock Therapeutics, Voyager Therapeutics, Axovant Gene Therapies, Sanofi, and Roche, all focused on innovative pipelines targeting dopamine restoration, neuronal repair, and disease modification.
Segmentation Analysis
By Product
• Gene therapy products (AAV-based vectors, lentiviral vectors)
• Cell therapy products (dopaminergic neuron transplants, stem cell-derived therapies)
• Combination therapies (gene + cell therapy approaches)
• Supportive biologics (neurotrophic factors)
By Platform
• Hospitals & specialized neurology centers
• Academic & research institutes
• Contract research and manufacturing organizations (CROs/CMOs)
By Technology
• Gene editing (CRISPR, TALENs)
• Viral vector-based delivery systems
• Stem cell transplantation
• Exosome-based delivery platforms
• Digital monitoring and AI-based trial optimization
By End Use
• Adult patients (ages 40-65)
• Geriatric patients (65+)
By Application
• Symptom management (dopamine restoration)
• Disease-modifying therapies (neuroprotection and regeneration)
• Research and clinical trials
Segmentation Summary
Gene therapy products dominate the pipeline due to strong clinical trial activity, but cell therapies are gaining momentum with advances in stem cell-derived dopaminergic neurons. Hospitals and academic centers remain the primary platforms, while CROs and CMOs play a critical role in supporting large-scale trials and manufacturing.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/72098/cell-and-gene-therapy-in-parkinson-s-disease-market
Regional Analysis
North America
• Largest market, driven by strong clinical trial activity, advanced healthcare infrastructure, and supportive FDA pathways for gene therapy approvals.
• The U.S. leads with significant funding and partnerships between biotech companies and academic institutions.
Europe
• Robust market supported by EMA's regulatory framework for ATMPs.
• Germany, France, and the UK dominate, with several ongoing cell and gene therapy trials.
Asia-Pacific
• Fastest-growing region due to expanding healthcare investment, large patient populations, and increasing participation in clinical trials.
• Japan, China, and South Korea are leading innovators in regenerative medicine and cell therapy.
Middle East & Africa
• Limited adoption but growing interest in advanced therapies in Gulf nations through private healthcare investment.
Latin America
• Emerging demand in Brazil, Mexico, and Argentina, supported by government programs in neuroscience and rare disease treatment.
Regional Summary
North America and Europe dominate revenues, while Asia-Pacific is expected to deliver the fastest growth through 2034 due to its focus on regenerative medicine and strong healthcare modernization initiatives.
Market Dynamics
Key Growth Drivers
• Rising prevalence of Parkinson's disease globally.
• Advancements in gene therapy platforms and stem cell technologies.
• Increasing government and private funding for neurodegenerative disease research.
• Regulatory incentives for orphan drugs and ATMPs.
Key Challenges
• High costs of development and treatment delivery.
• Manufacturing and scalability issues with cell and gene therapies.
• Long approval timelines for clinical trials.
• Limited specialized infrastructure in emerging economies.
Latest Trends
• Expansion of CRISPR-based therapies for precision medicine.
• Growing focus on personalized cell therapy approaches.
• Use of AI and big data to optimize trial design and patient selection.
• Collaborations between large pharma and biotech startups to accelerate innovation.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72098
Competitor Analysis
Major Players:
• Novartis AG
• Bayer AG
• BlueRock Therapeutics
• Voyager Therapeutics
• Axovant Gene Therapies Ltd.
• F. Hoffmann-La Roche Ltd.
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• CRISPR Therapeutics AG
• Editas Medicine Inc.
Competitive Summary
The market is highly innovation-driven, with a strong pipeline of clinical-stage candidates. Novartis and Bayer, through BlueRock Therapeutics, are advancing stem cell-derived therapies, while Voyager and Axovant focus on AAV-based gene therapies. Competition revolves around clinical trial success, regulatory approvals, and scalability of manufacturing processes. Partnerships and acquisitions remain critical strategies for strengthening portfolios.
Conclusion
The cell and gene therapy in Parkinson's disease market is projected to grow from USD 1.9 billion in 2024 to USD 5.2 billion by 2034, at a CAGR of 10.5%.
This report is also available in the following languages : Japanese (パーキンソン病における細胞・遺伝子治療市場), Korean (파킨슨병의 세포 및 유전자 치료 시장), Chinese (帕金森病的细胞和基因治疗市场), French (Thérapie cellulaire et génique dans la maladie de Parkinson - Marché), German (Zell- und Gentherapie bei Parkinson - Markt), and Italian (Terapia cellulare e genica nella malattia di Parkinson - Mercato), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/72098
Our More Reports:
Generalized anxiety disorder Patient Pool Analysis, Market
https://exactitudeconsultancy.com/reports/72126/generalized-anxiety-disorder-patient-pool-analysis-market
Vascular Dementia Patient Pool Analysis, Market
https://exactitudeconsultancy.com/reports/72128/vascular-dementia-patient-pool-analysis-market
Deep Brain Stimulation Devices Market
https://exactitudeconsultancy.com/reports/72130/deep-brain-stimulation-devices-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cell and Gene Therapy in Parkinson's Disease Market Growth, Applications, Innovations and Business Outlook by 2034 here
News-ID: 4189999 • Views: …
More Releases from Exactitude Consultancy
Parkinson's Disease Patient Pool Analysis Market Massive Growth opportunity Ahea …
Introduction
Parkinson's disease (PD) is a progressive neurodegenerative disorder marked by motor symptoms such as tremors, rigidity, bradykinesia, and postural instability, as well as non-motor symptoms including depression, cognitive impairment, and sleep disturbances. It is the second most common neurodegenerative disease after Alzheimer's, and its burden continues to rise globally due to aging populations and increasing life expectancy.
The Parkinson's disease patient pool analysis market plays a crucial role in quantifying patient…
Developmental and Epileptic Encephalopathies (DEE) Patient Pool Analysis Market …
Introduction
Developmental and Epileptic Encephalopathies (DEE) are a group of rare, severe pediatric epilepsies characterized by early-onset seizures, developmental delays, cognitive impairment, and high morbidity. DEEs include conditions such as Dravet syndrome, Lennox-Gastaut syndrome, Ohtahara syndrome, and West syndrome, among others. These disorders represent some of the most challenging areas in pediatric neurology due to limited treatment options and the significant burden on families and healthcare systems.
Growing awareness of rare pediatric…
Treatment-Resistant Depression (TRD) Market Growth, Trends, Consumer Demand and …
Introduction
Depression is one of the most common mental health disorders worldwide. While many patients respond positively to first-line antidepressant therapies, a significant proportion fail to achieve remission even after multiple treatment attempts. This subgroup is diagnosed with treatment-resistant depression (TRD), a severe and disabling condition that increases the risk of hospitalization, suicide, and chronic functional impairment.
With growing global recognition of mental health as a public health priority, there is an…
Primary Ciliary Dyskinesia (PCD) Market 2025-2034 Business Outlook, Critical Ins …
Introduction
Primary Ciliary Dyskinesia (PCD) is a rare, inherited disorder that affects the structure and function of cilia-tiny, hair-like structures that help move mucus, sperm, and other substances through the body. Malfunctioning cilia lead to chronic respiratory infections, sinusitis, ear infections, and in some cases, fertility problems. Because it is often underdiagnosed due to overlapping symptoms with other respiratory conditions, PCD poses significant diagnostic and management challenges.
With increasing attention on rare…
More Releases for Parkinson
Key Trends Reshaping the Wolff Parkinson White Syndrome Market: Technological Ad …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
Wolff Parkinson White Syndrome Market Size Growth Forecast: What to Expect by 2025?
The market for Wolff Parkinson White syndrome has registered consistent growth over the recent past. The expectation is that it will expand from $1.17 billion in 2024 to $1.22 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.5%.…
Evolving Market Trends In The Anti-Parkinson Drugs Industry: Innovative Advancem …
The Anti-Parkinson Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Anti-Parkinson Drugs Market Size During the Forecast Period?
The anti-parkinson drugs market has seen significant growth in recent years, projected to increase from $10.37 billion in 2024 to $11.08 billion in…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
Wolff Parkinson White Syndrome Treatment Market Overview 2024-2033
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Wolff Parkinson White Syndrome Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $1.43 billion…
Anti-Parkinson Drugs Market Overview
Exhibiting robust growth, the anti-parkinson drugs market is set to escalate from $9.73 billion in 2023 to $10.43 billion in 2024, with a notable Compound Annual Growth Rate (CAGR) of 7.2%. The trajectory continues on an upward trend, with an anticipated market size of $13.36 billion by 2028, sustaining a robust CAGR of 6.4%.
Increasing Geriatric Population Driving Demand:
The burgeoning geriatric population, coupled with a surge in Parkinson's disease cases,…
